- AbbVie Presents Data Adds to Robust IMBRUVICA® (ibrutinib) Science
- AbbVie Presents Data of Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
- AbbVie Presents Data for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
- Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
- Affimed provides updated clinical data from Ph 1/2 study of AFM13 precomplexed with cord blood-derived NKcells
- Body Of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta CAR T-Cell Therapy For Patients With R/R Large B-Cell Lymphoma
- Genentech Presents New and Updated Data for Polivy in 1L DLBCL
- Genmab Showcases Data From Epcoritamab (DuoBody-CD3xCD20) program in Patients Across a Broad Range of B-Cell Lymphomas
- Harpoon Therapeutics Presents Updated Interim Results for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
- IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies
- Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) + DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
- Janssen Presents New Data for Talquetamab Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
- Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib
- LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051
- MorphoSys Presents New Longer-term Ph 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity
- MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis
- New data underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
- New Results from the Ph 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated CLL
- Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
- Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
- Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703)
- Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis
- Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations
- Time To CAR T-Cell Therapy May Impact Outcomes For Patients With Relapsed/Refractory Large B-Cell Lymphoma In New CIBMTR Analysis
- Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat AML Populations